相关实验视频
Updated: Jun 29, 2025
10:44
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
Published on: February 22, 2015
10.3K
最近在治疗初级和二级渐进的多发性硬化症方面取得的进展
Shitiz Sriwastava1, Mahmoud Elkhooly2, Suban Amatya3
1Division of Multiple Sclerosis and Neuroimmunology Department of Neurology, McGovern Medical School (UT Health), University of Texas Health Science Center at Houston, Houston, TX,USA.
Journal of neuroimmunology
|March 30, 2024
概括
进展性多发性硬化症 (PPMS和SPMS) 的新疗法通过向炎症和复髓化,显示出有前途. 目前正在进行的试验探索BTK抑制剂,视多和干细胞疗法,以期望前景.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 初级和二级渐进性多发性硬化症 (PPMS和SPMS) 在神经治疗中构成重大挑战.
- 目前对PPMS和SPMS的治疗策略有限,需要探索新的治疗途径.
研究的目的:
- 审查和确定PPMS和SPMS的新兴治疗方法和正在进行的临床试验.
- 将这些潜在疗法的作用机制,疗效和安全性概况与现有治疗方法进行比较.
主要方法:
- 对正在进行的PPMS和SPMS临床试验的系统审查来源于NIH,PubMed,Embase和clinicaltrials.gov.gov.
- 分析自2010年以来发表的研究,重点关注新型治疗剂和策略.
主要成果:
- 布鲁顿的氨酸激酶抑制剂 (BTKI) 如托莱布鲁丁尼和费内布鲁丁尼正在接受研究.
- 维多弗鲁迪木斯证明了活跃和新出现的MRI病变的减少.
- 抗氧化疗法 (simvastatin,N-乙半氨酸,α-酸) 和实验性干细胞疗法 (AHSCT,介质干细胞疗法) 也正在探索中.
结论:
- 新兴的治疗方法为PPMS和SPMS患者提供了充满希望的前景,准炎症,复髓化和神经保护.
- 未来的研究应侧重于组合疗法,以解决渐进性多发性硬化症的复杂病原性,包括炎症,脱髓化和神经元损失.
相关概念视频
01:15Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
01:22Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
01:20Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264